Ethosuximide Orifarm (Ethosuximide)
Succinimide anticonvulsant for absence seizures and related epilepsy syndromes
Quick Facts About Ethosuximide Orifarm
Key Takeaways About Ethosuximide Orifarm
- First-line for absence seizures: Ethosuximide is the gold standard treatment for childhood absence epilepsy, recommended as first-line therapy by the International League Against Epilepsy (ILAE)
- Regular blood monitoring essential: Complete blood counts must be checked monthly during the first year and every six months thereafter to detect rare but serious bone marrow suppression
- Gradual dose titration: Treatment starts at 500 mg daily and is slowly increased every 5–7 days to minimize side effects, with a typical maintenance dose of 1,000–1,500 mg daily
- Avoid alcohol completely: Alcohol can unpredictably alter and enhance the effects of ethosuximide, increasing the risk of serious side effects
- Never stop abruptly: Sudden discontinuation can trigger rebound seizures or status epilepticus – always taper gradually under medical supervision
What Is Ethosuximide Orifarm and What Is It Used For?
Ethosuximide Orifarm is a prescription anticonvulsant medication used primarily to treat absence seizures (petit mal epilepsy). It belongs to the succinimide class of antiepileptic drugs and works by blocking low-threshold T-type calcium channels in the thalamus, thereby preventing the abnormal electrical discharges that cause absence seizures. It is approved for adults, elderly patients, and children over 6 years of age.
Ethosuximide was first introduced for clinical use in 1958 and has since become one of the most important medications in the treatment of absence epilepsy. It remains the first-line treatment recommended by the International League Against Epilepsy (ILAE) for childhood absence epilepsy, a position reinforced by the landmark Standard and New Antiepileptic Drugs (SANAD) trial and subsequent systematic reviews. The World Health Organization includes ethosuximide on its Model List of Essential Medicines, recognizing its critical role in epilepsy management worldwide.
Absence seizures are a specific type of generalized epileptic seizure characterized by brief episodes of staring and unresponsiveness, typically lasting 5 to 30 seconds. During an absence seizure, the person appears to "blank out" and may show subtle signs such as eye blinking or lip smacking. These seizures are most common in children between ages 4 and 14, and can occur dozens or even hundreds of times per day, significantly affecting school performance and quality of life. The electroencephalogram (EEG) during an absence seizure shows a characteristic 3 Hz (three per second) generalized spike-and-wave pattern.
Ethosuximide Orifarm is manufactured by Orifarm Generics A/S and contains 250 mg of ethosuximide per soft capsule. The capsules are oval, yellow, and opaque, measuring approximately 14 × 8 mm. They are designed for oral administration and should be taken during or after meals to reduce gastrointestinal side effects.
Approved Indications
- Absence seizures (petit mal epilepsy): The primary and most well-established indication for ethosuximide. It is effective for both typical and atypical absence seizures and is considered the treatment of choice for childhood absence epilepsy
- Myoclonic and myoclonic-atonic seizures in adolescents: Ethosuximide may be used as a second-line treatment for these seizure types when other antiepileptic drugs have proven ineffective or are not tolerated. Myoclonic seizures involve sudden, brief involuntary muscle jerks, while myoclonic-atonic seizures combine a brief jerk followed by a sudden loss of muscle tone
How Does Ethosuximide Work?
Ethosuximide exerts its anticonvulsant effect primarily by blocking low-threshold T-type calcium channels (specifically the Cav3.2 subtype, also known as α1H) in thalamic relay neurons. These T-type calcium channels play a critical role in generating the rhythmic thalamocortical oscillations that underlie the 3 Hz spike-and-wave discharges characteristic of absence seizures. By reducing T-type calcium currents, ethosuximide disrupts the synchronized neuronal firing pattern that produces the clinical manifestation of an absence seizure.
Research has shown that the thalamus acts as a pacemaker for absence seizures, with thalamic relay neurons switching between two firing modes: a tonic mode during normal wakefulness and a burst-firing mode during sleep or seizures. T-type calcium channels are essential for burst firing, and by inhibiting these channels, ethosuximide prevents the transition to the burst-firing mode that generates absence seizures. This highly specific mechanism of action explains why ethosuximide is particularly effective for absence seizures but is not useful for other seizure types such as tonic-clonic or focal seizures.
Additional mechanisms may also contribute to the therapeutic effect. Some evidence suggests that ethosuximide may also reduce certain persistent sodium currents and modulate calcium-activated potassium channels in thalamic neurons. These complementary actions further reduce thalamic neuronal excitability and reinforce its antiabsence efficacy.
What Should You Know Before Taking Ethosuximide Orifarm?
Before starting Ethosuximide Orifarm, your doctor must evaluate your blood counts and liver function. The medication is contraindicated in patients allergic to ethosuximide or other succinimides, and in patients with porphyria. Special caution is needed in patients with a history of psychiatric disorders, as psychological side effects including anxiety and hallucinations may occur.
Contraindications
Ethosuximide Orifarm must not be taken in the following situations:
- Allergy to ethosuximide or succinimides: If you have a known hypersensitivity to ethosuximide, any other succinimide anticonvulsant (such as methsuximide), or any of the inactive ingredients in the capsule (listed in the composition section below)
- Porphyria: Ethosuximide is contraindicated in patients with acute intermittent porphyria or other forms of hepatic porphyria, as it may precipitate a porphyric crisis. Porphyrias are a group of rare inherited metabolic disorders that affect the production of heme, a component of hemoglobin
Warnings and Precautions
Treatment with ethosuximide requires careful medical supervision. Discuss the following concerns with your doctor before and during treatment:
Ethosuximide can cause serious blood disorders including agranulocytosis (loss of white blood cells that fight infection), aplastic anemia (failure of the bone marrow to produce blood cells), and pancytopenia (deficiency of all types of blood cells). These conditions can be life-threatening. Your blood counts will be checked regularly – monthly during the first year and every six months thereafter. Seek immediate medical attention if you develop fever, sore throat, mouth ulcers, unusual bruising or bleeding, or persistent fatigue.
Movement disorders (dyskinesia): In rare cases, movement disorders may develop within the first 12 hours of starting treatment. If you experience involuntary movements, stop taking the medication and contact your doctor immediately. Your doctor may administer intravenous diphenhydramine as an antidote in severe cases.
Psychiatric effects: Psychological side effects including anxiety, hallucinations, and paranoia may occur, particularly in patients with a pre-existing history of psychiatric disorders. Your doctor will take special care when prescribing ethosuximide if you have had previous mental health conditions. Report any unusual changes in mood, behavior, or thinking to your doctor.
Suicidal thoughts: A small number of patients treated with antiepileptic medications, including ethosuximide, have experienced thoughts of self-harm or suicide. If you develop such thoughts at any time during treatment, contact your doctor immediately or seek emergency medical attention. This risk applies to all antiepileptic drugs and was identified through large-scale meta-analyses conducted by regulatory agencies.
Serious and potentially life-threatening skin reactions have been reported with ethosuximide, including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). Stop taking ethosuximide and seek immediate medical care if you develop: target-like or round reddish spots on the trunk, skin blistering or peeling, sores in the mouth, throat, nose, or eyes, widespread rash with fever, or swollen lymph nodes.
Liver function monitoring: Your liver enzymes will be monitored regularly throughout treatment. Ethosuximide is metabolized by the liver, and hepatic impairment may affect drug levels. Report any symptoms of liver problems such as yellowing of the skin or eyes (jaundice), dark urine, or persistent nausea to your doctor.
Lupus erythematosus: In rare cases, ethosuximide has been associated with the development of systemic lupus erythematosus (SLE) or lupus-like syndrome. Symptoms may include joint pain, skin rash (particularly a butterfly-shaped rash on the face), fever, and fatigue. Report any such symptoms to your doctor.
Combination Therapy
Absence seizures are frequently associated with generalized tonic-clonic seizures. Since ethosuximide is not effective against tonic-clonic seizures, your doctor may combine it with another antiepileptic drug such as primidone or phenobarbital to provide adequate protection against both seizure types. In childhood absence epilepsy without concurrent tonic-clonic seizures, ethosuximide monotherapy (treatment with ethosuximide alone) is usually sufficient.
How Does Ethosuximide Orifarm Interact with Other Drugs?
Ethosuximide interacts with several other medications, particularly other antiepileptic drugs. Carbamazepine may reduce ethosuximide levels, while valproate may increase them. Sedative medications may have enhanced effects when combined with ethosuximide. Always inform your doctor about all medications you are taking.
The following drug interactions are clinically significant and should be discussed with your prescribing physician:
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Carbamazepine | May decrease ethosuximide plasma levels through enzyme induction | Monitor ethosuximide levels; dose adjustment may be needed |
| Valproate (Valproic acid) | May increase ethosuximide plasma levels by inhibiting its metabolism | Monitor for increased side effects; dose reduction may be necessary |
| Phenytoin | May alter ethosuximide metabolism; variable effects reported | Monitor plasma levels of both drugs when used together |
| Phenobarbital / Primidone | May decrease ethosuximide levels through hepatic enzyme induction | Often combined intentionally for seizure control; monitor levels |
| Sedatives / Hypnotics | Mutual enhancement of sedative and sleep-inducing effects | Use caution; may increase drowsiness and impair alertness |
| Alcohol | Unpredictable alteration and enhancement of ethosuximide effects | Alcohol must be avoided completely during treatment |
If you are taking other antiepileptic drugs alongside ethosuximide, your doctor may need to monitor plasma drug levels more frequently to ensure optimal dosing. The complex pharmacokinetic interactions between antiepileptic drugs make therapeutic drug monitoring an essential part of combination therapy.
Food and Drink
Ethosuximide Orifarm should be taken during or after a meal with half a glass of water. Taking the medication with food helps to reduce gastrointestinal side effects such as nausea, vomiting, and stomach pain. Alcohol must be completely avoided during treatment, including foods and beverages that contain alcohol, as it can alter and enhance the effects of ethosuximide in unpredictable ways.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you might be pregnant, or are planning to have a baby, consult your doctor or pharmacist before taking this medication.
Pregnancy: If you are of childbearing age, your doctor should discuss the necessity of planning and monitoring any potential pregnancy before starting treatment with ethosuximide. While no specific malformations have been conclusively attributed to ethosuximide monotherapy, the risk of birth defects is generally higher for women taking antiepileptic drugs compared to the general population. The most commonly reported malformations with antiepileptic drugs in general include cleft lip, cardiovascular malformations, and neural tube defects (spina bifida). This risk is further increased when multiple antiepileptic drugs are used simultaneously, and combination therapy should therefore be avoided during pregnancy whenever possible.
The lowest effective dose that maintains seizure control should be used, particularly between days 20 and 40 of pregnancy (the critical period for organ development). Ethosuximide blood levels should be monitored regularly during pregnancy, and folic acid supplementation is recommended for women who are planning pregnancy or who are pregnant while taking ethosuximide. To prevent vitamin K1 deficiency and associated bleeding in the newborn, vitamin K1 supplementation should be given during the final month of pregnancy.
Do not stop taking ethosuximide without first consulting your doctor, as uncontrolled seizures can also pose serious risks to both the mother and the unborn child.
Breastfeeding: Ethosuximide passes into breast milk in significant quantities. Breastfeeding is not recommended during treatment with ethosuximide due to the potential risk of adverse effects on the nursing infant.
Fertility: The effects of ethosuximide on human fertility have not been studied. Discuss any fertility concerns with your healthcare provider.
Driving and Operating Machinery
Ethosuximide Orifarm may impair your reaction time and cognitive function. This is particularly important during the initial adjustment phase of treatment. You should not drive motor vehicles, operate dangerous power tools, or work without a secure grip during the entire treatment period, especially when doses are being adjusted. Be aware that drowsiness, dizziness, and other side effects may affect your ability to react quickly and purposefully to unexpected events. You are personally responsible for assessing whether you are fit to drive or perform tasks that require alertness. Discuss this with your doctor or pharmacist if you are uncertain.
What Is the Correct Dosage of Ethosuximide Orifarm?
The recommended starting dose for adults and children over 6 years is 500 mg daily (2 capsules). The dose is gradually increased every 5–7 days in steps of up to 250 mg until seizure control is achieved, typically at a daily dose of 1,000–1,500 mg (4–6 capsules). In exceptional cases, doses up to 2,000 mg daily may be required.
Always take Ethosuximide Orifarm exactly as prescribed by your doctor. Your epilepsy specialist will determine the optimal dose based on your individual response, seizure frequency, and plasma drug levels. The therapeutic plasma concentration range for ethosuximide is generally considered to be 40–100 mcg/mL (283–708 µmol/L).
Adults and Elderly
Adult Dosing Schedule
Starting dose: 500 mg per day (2 capsules), taken in divided doses or as a single dose
Dose titration: Increase by up to 250 mg every 5–7 days, depending on tolerability
Maintenance dose: 1,000–1,500 mg per day (4–6 capsules), divided into multiple doses
Maximum dose: 2,000 mg per day (8 capsules) in exceptional cases, divided into several doses
Children (Over 6 Years)
Pediatric Dosing Schedule (Over 6 Years)
Starting dose: 500 mg per day (2 capsules)
Dose titration: Increase by up to 250 mg every 5–7 days based on the child's tolerance
Maintenance dose: 1,000–1,500 mg per day (approximately 20–30 mg/kg/day)
Note: This capsule formulation is not suitable for young children (0–6 years) or individuals who cannot swallow capsules. An oral solution formulation may be available for these patients.
Hemodialysis Patients
Dosing in Hemodialysis
Ethosuximide is removed from the body during dialysis. During a four-hour dialysis session, approximately 39–52% of the administered dose is eliminated. Hemodialysis patients therefore require a supplemental dose or a modified dosing schedule. Your nephrologist and neurologist will work together to determine the appropriate dosing adjustments.
| Patient Group | Starting Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Adults | 500 mg/day | 1,000–1,500 mg/day | 2,000 mg/day |
| Elderly | 500 mg/day | 1,000–1,500 mg/day | 2,000 mg/day |
| Children (>6 years) | 500 mg/day | 20–30 mg/kg/day | 2,000 mg/day |
| Hemodialysis | Individualized | Supplemental dose post-dialysis | Based on plasma levels |
Duration of Treatment
Epilepsy treatment with ethosuximide is generally a long-term therapy. The size of your dose, how it should be distributed throughout the day, and when and how you should discontinue treatment will be determined by a specialist experienced in epilepsy management. Regular follow-up appointments are essential to assess treatment effectiveness, monitor for side effects, and adjust the dose as needed.
If seizures have been well controlled for at least two years, your doctor may consider gradually tapering the dose to determine whether treatment can be discontinued. This process should always be done slowly and under close medical supervision, as abrupt discontinuation can trigger rebound seizures.
Missed Dose
If you miss a dose, do not take a double dose to make up for the missed one. Simply continue with your normal dosing schedule as prescribed. Missing a single dose usually does not cause symptoms, but remember that ethosuximide only controls your epilepsy effectively if taken regularly. If you frequently forget to take your medication, discuss this with your doctor or pharmacist who can suggest strategies to improve adherence.
Overdose
If you accidentally take a double dose, do not change your dosing schedule – continue taking Ethosuximide Orifarm as prescribed by your doctor. If you or someone else has taken a significantly excessive amount of the medication, contact your doctor, hospital, or poison control center immediately.
Symptoms of ethosuximide overdose may include:
- Excessive drowsiness and lethargy
- Depressive states and anxiety
- Irritability (in some cases)
- Nausea and vomiting
- Respiratory depression (in severe cases)
- Coma (in very severe cases)
These symptoms may be worsened by alcohol or other substances that affect the central nervous system. There is no specific antidote for ethosuximide overdose; treatment is supportive and may include gastric lavage, activated charcoal, and monitoring of vital functions. Hemodialysis may be effective in removing ethosuximide from the body in severe cases.
What Are the Side Effects of Ethosuximide Orifarm?
The most common side effects of Ethosuximide Orifarm are gastrointestinal symptoms (nausea, vomiting, abdominal pain, hiccups), drowsiness, dizziness, skin rash, and hives. Serious but rare side effects include blood disorders (agranulocytosis, aplastic anemia), severe skin reactions (Stevens-Johnson syndrome, DRESS), and psychiatric disturbances (psychosis, hallucinations). Many side effects are dose-dependent and can be minimized by gradual dose titration.
Like all medicines, Ethosuximide Orifarm can cause side effects, although not everybody gets them. The following list includes side effects reported during clinical use and post-marketing surveillance. The risk of dose-dependent side effects can be reduced by starting treatment at a low dose, increasing gradually, and taking the medication with food.
Stop taking Ethosuximide Orifarm and seek immediate medical care if you experience any of the following serious side effects: psychosis (delusions, hallucinations), signs of severe blood disorders (persistent fever, severe sore throat, unusual bleeding or bruising), target-like skin spots or blistering (Stevens-Johnson syndrome), widespread rash with fever and swollen lymph nodes (DRESS).
Common to Very Common
- Nausea
- Vomiting
- Abdominal pain
- Hiccups
- Drowsiness
- Dizziness
- Skin rash
- Urticaria (hives)
Uncommon
- Severe headache
- Lethargy (apathy, listlessness)
- Ataxia (movement disorders, unsteady gait)
- Difficulty concentrating
- Withdrawal syndrome
- Anxiety
- Sleep disturbances
- Suicidal thoughts
- Psychosis (delusions, hallucinations)
- Decreased appetite and weight loss
- Diarrhea
- Constipation
- Swollen gums
- Swollen tongue
- Fatigue
- Irritability
Rare
- Agranulocytosis (loss of certain infection-fighting white blood cells)
- Thrombocytopenia (low platelet count, causing easy bruising and bleeding)
- Paranoia and hallucinations developing over days to weeks
- Lupus erythematosus (autoimmune skin and organ condition)
- Leukopenia (low white blood cell count)
- Eosinophilia (elevated eosinophil white blood cells)
- Myopia (nearsightedness)
- Blood in the urine (hematuria)
Not Known
- Stevens-Johnson syndrome (severe skin reaction with blistering and peeling)
- DRESS (drug reaction with eosinophilia and systemic symptoms)
- Aplastic anemia (bone marrow failure to produce blood cells)
- Pancytopenia (deficiency of all blood cell types)
- Dyskinesia (involuntary movements, typically within first 12 hours of treatment)
- Depression
- Restless agitation
Long-term treatment with ethosuximide may affect cognitive performance. This is particularly relevant for children and adolescents in educational settings, where subtle cognitive effects may influence academic performance. Regular assessments by your doctor and, where appropriate, neuropsychological evaluations can help identify and manage any cognitive impacts. These effects are generally reversible upon dose reduction or discontinuation.
Dose-dependent side effects can often be managed by adjusting the dose downward or by taking the medication with meals. Side effects that are independent of dose typically resolve when the medication is discontinued but may recur if treatment is restarted. Report any side effects to your doctor so they can assess the severity and determine the appropriate course of action.
How Should You Store Ethosuximide Orifarm?
Store Ethosuximide Orifarm below 30°C, in the original packaging, and out of the sight and reach of children. Do not use after the expiry date printed on the carton.
Proper storage is important to maintain the effectiveness and safety of your medication. Follow these guidelines:
- Store below 30°C: Keep the capsules at room temperature, avoiding excessive heat
- Keep out of the sight and reach of children at all times
- Do not use after the expiry date stated on the carton after "EXP." The expiry date refers to the last day of that month
- Store in the original packaging to protect from light and moisture
- Do not dispose of medications in household waste or wastewater. Return unused medicines to your pharmacy for safe disposal to protect the environment
What Does Ethosuximide Orifarm Contain?
Each soft capsule contains 250 mg of ethosuximide as the active ingredient. The capsule also contains macrogol, gelatin, glycerol, sorbitol, purified water, titanium dioxide, and yellow iron oxide. Each capsule contains 13.7 mg of sorbitol.
Active Ingredient
Each soft capsule contains 250 mg of ethosuximide (2-ethyl-2-methylsuccinimide), a member of the succinimide class of anticonvulsant drugs.
Inactive Ingredients
The other ingredients are: macrogol (polyethylene glycol), gelatin, glycerol (E422), partially dehydrated liquid sorbitol (E420), purified water, titanium dioxide (E171), and yellow iron oxide (E172). These excipients form the soft gelatin capsule shell and give it its characteristic oval, yellow, opaque appearance.
Sorbitol Content
This medicine contains 13.7 mg of sorbitol per capsule. Sorbitol is a sugar alcohol that is used as an excipient in the capsule formulation. Patients with hereditary fructose intolerance should be aware of this ingredient and consult their doctor before taking this medication.
Appearance and Pack Sizes
Ethosuximide Orifarm capsules are oval, yellow, and opaque soft capsules measuring 14 × 8 mm. They are available in blister packs of 50, 100, or 200 soft capsules. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Ethosuximide Orifarm
Both ethosuximide and valproate (sodium valproate) are effective treatments for absence seizures. The landmark SANAD trial showed that ethosuximide and valproate had similar seizure-freedom rates, but ethosuximide had fewer adverse effects on attention and cognitive function. Ethosuximide is therefore preferred as the first-line treatment for childhood absence epilepsy when absence seizures are the only seizure type. However, valproate is preferred when both absence seizures and generalized tonic-clonic seizures are present, as ethosuximide is not effective against tonic-clonic seizures. The choice between the two should be made by your epilepsy specialist based on your specific seizure type, age, sex, and other individual factors.
Ethosuximide should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus. While no specific birth defects have been conclusively linked to ethosuximide alone, all antiepileptic drugs carry a generally increased risk of congenital malformations. The lowest effective dose should be used, combination therapy should be avoided, and folic acid supplementation is recommended. Blood levels should be monitored regularly throughout pregnancy. Importantly, do not stop taking your medication without consulting your doctor, as uncontrolled seizures can also be dangerous for both mother and baby. Breastfeeding is not recommended during treatment.
Ethosuximide begins to have a therapeutic effect once steady-state blood levels are reached, which typically takes about 7–10 days with a consistent dose (given its long half-life of 40–60 hours in adults). However, since treatment starts at a low dose and is gradually increased, it may take several weeks to reach the optimal therapeutic dose. Your doctor will assess seizure frequency and may order EEG recordings to evaluate treatment effectiveness. Do not increase the dose faster than recommended, as this increases the risk of side effects.
Stopping ethosuximide suddenly can be dangerous. Abrupt discontinuation may trigger rebound absence seizures, which can be more frequent and severe than before treatment. In some cases, it may even precipitate absence status epilepticus, a prolonged episode of continuous or rapidly recurring absence seizures. If you and your doctor decide to discontinue treatment, the dose will be reduced gradually over weeks to months. Never change your dose or stop taking the medication without medical guidance.
The capsule formulation of Ethosuximide Orifarm is not suitable for children under 6 years of age or for anyone who cannot swallow capsules. For younger children who require ethosuximide treatment, an oral solution (syrup) formulation may be available under different brand names. Your pediatric neurologist will determine the most appropriate formulation and dose for your child based on their age, weight, and specific epilepsy syndrome.
No. Alcohol must be completely avoided while taking Ethosuximide Orifarm. Alcohol can alter and enhance the effects of ethosuximide in unpredictable ways, potentially causing excessive drowsiness, impaired coordination, and increased risk of seizures. This applies to all alcoholic beverages as well as foods containing alcohol. Even small amounts of alcohol can interact with the medication. If you have questions about specific foods or beverages, consult your pharmacist.
References
- Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine. 2010;362(9):790-799.
- Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141-155.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Ethosuximide listed as an essential anticonvulsant.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. Updated 2024.
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. The Lancet. 2007;369(9566):1016-1026.
- Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Annals of Neurology. 1989;25(6):582-593.
- European Medicines Agency (EMA). Ethosuximide – Summary of Product Characteristics. Updated 2025.
- International League Against Epilepsy (ILAE). Updated classification and management of epilepsy syndromes. Epilepsia. 2022;63(6):1331-1348.
- Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews. 2005;(4):CD003032.
- FDA Drug Safety Communication. Suicidality and antiepileptic drugs. U.S. Food and Drug Administration. Updated 2023.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes specialists in neurology, clinical pharmacology, and pediatric epileptology. All content follows international clinical guidelines and is based on evidence level 1A (systematic reviews and meta-analyses of randomized controlled trials).
All drug information is independently verified against official sources including EMA Summary of Product Characteristics (SmPC), FDA prescribing information, and WHO essential medicines guidelines. Content is updated whenever new safety information becomes available.
iMedic receives no funding from pharmaceutical companies. All content is editorially independent. Our editorial team has no financial relationships with any manufacturer of the medications described.